RAS mutations, including KRAS, sensitize cancer cells, including pancreatic ductal adenocarcinoma (PDAC) cells, to ferroptosis induction due to mutant RAS-mediated expression of iron metabolism genes, such as Tfrc, Fth1, and Ftl59. Here, KRAS is linked to pancreatic ductal adenocarcinoma.